The ligands L 1 and L 2 both form separable dinuclear double-stranded helicate and mesocate complexes with Ru II .In contrast to clinically approved platinates,the helicate isomer of [Ru 2 (L 1 ) 2 ] 4+ was preferentially cytotoxic to isogenic cells (HCT116 p53 À/À ), which lackt he critical tumour suppressor gene.T he mesocate isomer shows the reverse selectivity,w ith the achiral isomer being preferentially cytotoxict owards HCT116 p53 +/+ .O ther structurally similar Ru II -containing dinuclear complexes showed very little cytotoxic activity.T his study demonstrates that alterations in ligand or isomer can have profound effects on cytotoxicity towards cancer cells of different p53 status and suggests that selectivity can be "tuned" to either genotype.Inthe search for compounds that can target difficult-to-treat tumours that lackt he p53 tumour suppressor gene,[ Ru 2 (L 1 ) 2 ] 4+ is ap romising compound for further development. Dr.R .T .Wheelhouse School of Pharmacy,U niversity of Bradford Bradford BD7 1DP (UK) Supportinginformation and the ORCID identification number(s) for the author(s) of this article can be found under: https://doi.